Sponsor study identifier
Secondary identifiers
observational
10
0 countries
N/A
Study Start
May 2006
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
March 2008
Actual (reported)Study Completion
February 2009
Actual (reported)RATIONALE: Studying samples of blood and urine in the laboratory from patients with cancer receiving epidermal growth factor receptor inhibitors may help doctors understand the effect of epidermal growth factor receptor inhibitors on magnesium levels in the body. PURPOSE: This laboratory study is looking at the effect of epidermal growth factor receptor inhibitors on magnesium homeostasis in patients with cancer.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 2009
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 2006
Date type not reportedThis date has not been verified as actual or estimated.
March 2008
Actual (reported)February 2009
Actual (reported)May 9, 2009
Actual (reported)May 12, 2009
Actual (reported)Effects of EGFR inhibitors on magnesium homeostasis
8 weeks
laboratory biomarker analysis
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Individuals with the diagnosis of a malignancy for which they are considering therapy with an inhibitor of the EGFR pathway, have received an inhibitor of the EGFR pathway prior to study start, have no severe underlying renal dysfunction as defined as estimated GFR\<60 by MDRD equation and must be ≥ 18 years of age.
Laura Goff, MD
Vanderbilt-Ingram Cancer Center
10 participants (actual enrollment reported by the registry).
First Submitted
May 9, 2009
First Posted
May 12, 2009
Study Start
May 2006
Date type not reportedThis date has not been verified as actual or estimated.
A Study of the Safety and Tolerability of the Addition of CHR-2797 to Paclitaxel in Patients With Advanced or Refractory Tumours
Contact the study team to confirm eligibility.
Primary Completion
March 2008
Actual (reported)Study Completion
February 2009
Actual (reported)Last Updated
January 29, 2013
Record last verified: 2013-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: